Get the Stockscreener App
0.8578
1.20%
0.0102
Sutro Biopharma Inc stock is traded at $0.8578, with a volume of 464.71K.
It is up +1.20% in the last 24 hours and up +0.09% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
See More
Previous Close:
$0.8476
Open:
$0.836
24h Volume:
464.71K
Relative Volume:
0.59
Market Cap:
$72.72M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-0.4819
EPS:
-1.78
Net Cash Flow:
$-115.93M
1W Performance:
-2.30%
1M Performance:
+0.09%
6M Performance:
-51.54%
1Y Performance:
-81.15%
1-Day Range:
$0.8319
$0.8798
1-Week Range:
$0.8048
$0.9585
52-Week Range:
$0.5231
$5.17
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
0.8578 | 77.55M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
Sutro Biopharma Inc. stock volume spike explainedWeekly Profit Recap & Consistent Growth Equity Picks - Newser
How Sutro Biopharma Inc. stock performs during market volatilityJuly 2025 Big Picture & Weekly Top Performers Watchlists - beatles.ru
Tools to monitor Sutro Biopharma Inc. recovery probability2025 Valuation Update & Daily Chart Pattern Signals - Newser
How to forecast Sutro Biopharma Inc. trends using time seriesJuly 2025 Intraday Action & Expert Verified Movement Alerts - Newser
Is Sutro Biopharma Inc. trending in predictive chart modelsEarnings Recap Report & Fast Entry Momentum Alerts - Newser
Will Sutro Biopharma Inc. Benefit From Sector TailwindsQuarterly Portfolio Summary & Proven Capital Preservation Tips - Newser
Volume spikes in Sutro Biopharma Inc. stock – what they meanCPI Data & Weekly Breakout Stock Alerts - Newser
Ranking Sutro Biopharma Inc. among high performing stocks via toolsJuly 2025 Trade Ideas & Technical Entry and Exit Alerts - Newser
Detecting support and resistance levels for Sutro Biopharma Inc.July 2025 Momentum & Short-Term Swing Trade Alerts - Newser
Is Sutro Biopharma Inc. stock poised for growth2025 Volatility Report & Daily Oversold Bounce Ideas - Newser
Combining price and volume data for Sutro Biopharma Inc.2025 Winners & Losers & Precise Trade Entry Recommendations - Newser
Full technical analysis of Sutro Biopharma Inc. stockMarket Trend Review & Verified Technical Signals - Newser
Chart based analysis of Sutro Biopharma Inc. trendsMarket Movers & AI Based Trade Execution Alerts - Newser
Quantitative breakdown of Sutro Biopharma Inc. recent moveQuarterly Profit Summary & Weekly Top Performers Watchlists - Newser
Pattern recognition hints at Sutro Biopharma Inc. upside2025 Pullback Review & Real-Time Stock Price Movement Reports - Newser
Real time scanner hits for Sutro Biopharma Inc. explained2025 Earnings Surprises & Verified Technical Trade Signals - Newser
Understanding Sutro Biopharma Inc.’s price movementChart Signals & Free Fast Gain Swing Trade Alerts - Newser
Visualizing Sutro Biopharma Inc. stock with heatmapsTake Profit & Risk Adjusted Buy and Sell Alerts - Newser
Has Sutro Biopharma Inc. found a price floorTrade Volume Report & High Return Stock Watch Alerts - Newser
Sutro Biopharma Inc. stock momentum explainedJuly 2025 Trade Ideas & Fast Exit and Entry Strategy Plans - Newser
Strategies to average down on Sutro Biopharma Inc.2025 Dividend Review & Community Driven Trade Alerts - Newser
Will Sutro Biopharma Inc. Reverse From Oversold ConditionsJuly 2025 Pullbacks & Real-Time Stock Price Movement Reports - beatles.ru
What is the target price for Sutro Biopharma Inc. stockFree Growth Stock Screener - thegnnews.com
Sutro Biopharma price target lowered to $3 from $4 at Wells Fargo - TipRanks
Sutro Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Real time breakdown of Sutro Biopharma Inc. stock performanceFree Day Trading Signals With High Precision - Newser
Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Wall Street Zen - Defense World
Has Sutro Biopharma Inc. formed a bullish divergenceMomentum Detection with Entry Optimization - Newser
Sutro Biopharma Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates - MSN
Sutro Biopharma's Strategic Turnaround: A Path to Profitability Amidst Industry Challenges - AInvest
Sutro Biopharma’s Strategic Shift and Pipeline Developments: A Hold Rating Amid Transitional Phase - TipRanks
Sutro Biopharma Advances ADC Pipeline and Reports Q2 2025 Results - TipRanks
Sutro Biopharma 2025 Q2 Earnings Significant Net Loss Reduction - AInvest
SUTRO BIOPHARMA, INC. SEC 10-Q Report - TradingView
Sutro Biopharma earnings beat by $0.27, revenue topped estimates - Investing.com Canada
SUTRO BIOPHARMA Earnings Results: $STRO Reports Quarterly Earnings - Quiver Quantitative
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Advances Pipeline with Strategic Initiatives - Quiver Quantitative
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
Sutro Reports 148% Revenue Growth as ADC Pipeline Expands, FDA Partnership Accelerates Development - Stock Titan
Chart overlay techniques for tracking Sutro Biopharma Inc.Low Drawdown Picks with Weekly Updates - Newser
Sutro Biopharma Q2 revenue rises to $63.7 mln, net loss narrows - MarketScreener
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sutro Biopharma Inc Stock (STRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
37,849 |
0 |
133,282 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
2,500 |
0 |
54,580 |
| Borgman Anne Elizabeth | CHIEF MEDICAL OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
69,063 |
0 |
122,161 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
Apr 11 '25 |
Option Exercise |
0.00 |
21,250 |
0 |
59,683 |
| NEWELL WILLIAM J | CEO |
Mar 05 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
299,239 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
99,027 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 05 '25 |
Option Exercise |
0.00 |
8,750 |
0 |
135,675 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 04 '25 |
Option Exercise |
0.00 |
9,125 |
0 |
94,025 |
| NEWELL WILLIAM J | CEO |
Mar 04 '25 |
Option Exercise |
0.00 |
31,125 |
0 |
291,625 |
| Chung Jane | PRESIDENT AND COO |
Mar 04 '25 |
Option Exercise |
0.00 |
7,875 |
0 |
100,642 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):